Stifel Nicolaus restated their buy rating on shares of Indivior PLC (LON:INDV) in a research report report published on Friday morning. They currently have a GBX 400 ($5.39) target price on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Numis Securities Ltd reissued a buy rating and issued a GBX 490 ($6.61) target price on shares of Indivior PLC in a research report on Thursday, July 27th. Jefferies Group LLC reissued a buy rating and issued a GBX 490 ($6.61) target price on shares of Indivior PLC in a research report on Wednesday, June 7th. Citigroup Inc. reissued a neutral rating and issued a GBX 280 ($3.78) target price on shares of Indivior PLC in a research report on Tuesday, September 5th. Finally, Royal Bank Of Canada reissued an outperform rating and issued a GBX 470 ($6.34) target price on shares of Indivior PLC in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of GBX 395.50 ($5.33).

Shares of Indivior PLC (LON INDV) opened at 299.90 on Friday. The firm’s market cap is GBX 2.16 billion. Indivior PLC has a 12-month low of GBX 246.50 and a 12-month high of GBX 421.50. The company’s 50 day moving average price is GBX 368.73 and its 200-day moving average price is GBX 336.01.

ILLEGAL ACTIVITY WARNING: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/19/indivior-plcs-indv-buy-rating-reiterated-at-stifel-nicolaus.html.

Indivior PLC Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Stock Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related stocks with our FREE daily email newsletter.